Canaccord initiated coverage of Canopy Growth (CGC) with a Buy rating and C$2 price target Canopy is a leading cannabis company producing, distributing, and selling a “diverse range” of cannabis and cannabis-related products in key, global adult-use and medical cannabis markets, the analyst tells investors in a research note. The firm says the company’s pivot from an asset-light, third-party supply model to an asset-right, in-house supply model will improve its global competitive positioning.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGC:
- Congressman introduces bill for cannabis businesses to list on stock exchanges
- Study says cannabis shows little benefit for mental disorders, Reuters says
- Canopy Growth Closes MTL Cannabis Deal to Cement Lead in Medical Market
- Canopy Growth Wins MTL Cannabis Shareholder Backing for Acquisition
- Largest borrow rate increases among liquid names